List of Excipients in Branded Drug TAGRISSO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	TAGRISSO	osimertinib	0310-1349	CELLULOSE, MICROCRYSTALLINE	2032-07-25
AstraZeneca Pharmaceuticals LP	TAGRISSO	osimertinib	0310-1349	FERRIC OXIDE RED	2032-07-25
AstraZeneca Pharmaceuticals LP	TAGRISSO	osimertinib	0310-1349	FERRIC OXIDE YELLOW	2032-07-25

Tagrisso Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Tagrisso (osimertinib mesylate) is a high-value oral oncology product with a relatively simple immediate-release tablet formulation. Its excipient profile creates opportunities in generic development, direct excipient supply, formulation optimization, manufacturing services, and differentiated oral dosage forms. The principal commercial constraint is regulatory and patent timing, not formulation complexity.

A generic developer does not need to reproduce every excipient in Tagrisso. It must demonstrate pharmaceutical equivalence, acceptable product quality, and bioequivalence under the applicable FDA pathway. The most attractive opportunities involve excipient substitutions that preserve dissolution, stability, tablet robustness, and low-dose content uniformity while reducing cost or manufacturing risk.

What excipients are used in Tagrisso tablets?

Tagrisso is supplied as 40 mg and 80 mg film-coated tablets containing osimertinib mesylate. The FDA-approved label identifies the core excipients as mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. The film coating contains hypromellose, talc, titanium dioxide, and colorants, including iron oxides.[1]

Formulation component	Tagrisso function	Commercial relevance
Mannitol	Diluent and bulking agent	Supports tablet mass and mouthfeel; useful in low-dose formulations
Microcrystalline cellulose	Diluent and dry-binder	Improves compressibility and tablet strength
Low-substituted hydroxypropyl cellulose	Disintegrant and matrix-supporting excipient	Controls tablet breakup and dissolution
Sodium stearyl fumarate	Lubricant	Reduces ejection force with lower hydrophobicity than some stearate lubricants
Hypromellose	Film-forming polymer	Supports coating integrity and appearance
Talc	Anti-tacking and coating aid	Improves coating processability
Titanium dioxide	Opacifier and pigment	Supports color uniformity and light protection
Iron oxides	Colorants	Distinguish strengths and reproduce product appearance

The composition is consistent with a conventional immediate-release, film-coated tablet. Tagrisso does not require a lipid vehicle, enteric coating, modified-release polymer, or biologic stabilizer.

How does the Tagrisso formulation affect generic development?

The formulation is technically accessible for a competent generic manufacturer. The key development issues are low-dose uniformity, dissolution matching, tablet mechanical properties, and stability of the active pharmaceutical ingredient.

Low-dose content uniformity

The 40 mg tablet contains a relatively small quantity of active ingredient compared with the total tablet mass. Blend uniformity and segregation control therefore matter. Mannitol and microcrystalline cellulose provide a workable dilution platform, but particle-size distribution, density, and mixing energy can affect uniformity.

A generic manufacturer may use the same excipient classes with different grades or ratios. The strongest development strategy is usually a formulation that limits sensitivity to:

• Active-ingredient particle-size variation
• Blend segregation
• Lubrication time
• Compression-force changes
• Scale-up shear and residence time

Continuous manufacturing and engineered co-processed excipients could reduce blend variability, but the regulatory burden rises if the process differs materially from a conventional batch process.

Dissolution performance

Low-substituted hydroxypropyl cellulose contributes to disintegration. Excessive lubricant or over-compression can slow tablet breakup and dissolution. The formulation should be assessed across clinically relevant pH conditions and under accelerated stability conditions.

For a generic product, dissolution similarity can be more commercially important than exact excipient matching. A formulation that uses sodium stearyl fumarate, magnesium stearate, or another lubricant may be viable if it maintains comparable release and bioequivalence.

Tablet robustness

The commercial product must withstand high-volume bottling, shipping, blistering, and repeated handling. Microcrystalline cellulose supports mechanical strength, while the film coat reduces abrasion and improves visual differentiation between the 40 mg and 80 mg strengths.

Potential failure modes include:

• Capping or lamination during compression
• Tablet edge chipping
• Coating defects
• Color drift between batches
• Moisture-related dissolution changes
• Excessive friability after scale-up

These are manufacturing risks rather than fundamental formulation barriers.

What formulation patents protect Tagrisso?

Tagrisso protection is primarily associated with osimertinib composition, therapeutic use, and pharmaceutical formulation rights rather than a highly complex excipient system.

A patent review should separate four claim categories:

1. Osimertinib and related chemical compounds
2. Osimertinib mesylate and pharmaceutical compositions
3. Treatment of EGFR-mutated non-small-cell lung cancer
4. Specific dosing regimens and resistance settings

The presence of common excipients such as mannitol, microcrystalline cellulose, hypromellose, and sodium stearyl fumarate does not by itself create a strong formulation barrier. These materials are widely used in oral solid dosage products and are generally available from multiple suppliers.

The relevant patent risk may instead arise from claims covering:

• A particular crystalline or salt form
• Particle-size specifications
• Specific tablet composition ranges
• Stability-enhancing manufacturing conditions
• Combination treatment with other anticancer agents
• Use in adjuvant or metastatic EGFR-mutated lung cancer
• Treatment after progression on earlier EGFR inhibitors

A freedom-to-operate analysis must compare the proposed product and labeling against live claims in the United States, Europe, Japan, China, and other launch markets. Patent scope can differ materially by jurisdiction.

When does Tagrisso lose exclusivity?

Tagrisso received FDA approval in November 2015. Its five-year new chemical entity exclusivity period expired in November 2020, allowing ANDA applicants to submit applications earlier, subject to patent certification requirements.[2]

Exclusivity or protection category	Tagrisso position
FDA approval	November 2015
NCE exclusivity	Expired in 2020
Small-molecule product	Yes
Biosimilar pathway	Not applicable
Generic pathway	ANDA
Pediatric exclusivity	Must be confirmed against current FDA records
Patent protection	Multiple patents and use claims may extend beyond NCE exclusivity
First generic launch timing	Depends on patent challenges, settlements, court outcomes, and regulatory approval

The commercial launch date for a generic is not determined by NCE exclusivity alone. Orange Book-listed patents, Paragraph IV litigation, settlement agreements, pediatric exclusivity, and regulatory review timing can each affect market entry.

What is the Orange Book status of Tagrisso?

Tagrisso is listed in the FDA Orange Book as a prescription drug with approved tablet strengths of 40 mg and 80 mg. Orange Book listings may include patents directed to the active ingredient, formulation, method of use, or other approved aspects of the product.[3]

For a generic applicant, the central regulatory distinction is between:

• Paragraph I certification: no relevant patent is listed
• Paragraph II certification: listed patent has expired
• Paragraph III certification: applicant will wait until patent expiry
• Paragraph IV certification: applicant asserts that a listed patent is invalid, unenforceable, or not infringed

A Paragraph IV filing can trigger litigation within 45 days of notice to the patent holder. Litigation may impose a 30-month stay on FDA approval unless the case is resolved earlier or the stay is otherwise terminated under the Hatch-Waxman framework.[4]

The commercial value of a Paragraph IV challenge depends on the patent claim being targeted. A challenge to a broad compound patent has a different risk profile from a challenge to a narrower method-of-use patent that may be carved out through labeling.

Which companies are challenging Tagrisso exclusivity?

Public generic activity can include ANDA filings, patent litigation, settlement agreements, and tentative approvals. The relevant companies are not limited to the largest generic manufacturers. Specialty pharmaceutical companies and regional manufacturers may also pursue osimertinib.

The principal competitive groups are:

• Large generic manufacturers with oncology portfolios
• Indian and Israeli companies with ANDA and Paragraph IV capabilities
• Regional manufacturers targeting Europe, India, China, and other non-U.S. markets
• Contract development and manufacturing organizations developing alternative tablet platforms
• Excipients and formulation suppliers supporting multiple generic applicants

A complete challenger assessment should review PACER litigation, FDA tentative approvals, Orange Book certifications, and company patent disclosures. Patent disputes can remain commercially significant even when a generic has completed formulation development.

What excipient opportunities exist for Tagrisso generics?

The largest excipient opportunity is not a single proprietary ingredient. It is a validated package of excipients, grades, and process parameters that reduces development time and manufacturing variability.

Co-processed excipients

Co-processed mannitol-cellulose systems could improve flow, compactibility, and content uniformity. These products may reduce the number of formulation variables during scale-up. Suppliers can compete on:

• Flowability
• Compressibility
• Low-dose blend uniformity
• Moisture control
• Lot-to-lot consistency
• Compatibility with direct compression

A co-processed system cannot be marketed as a Tagrisso substitute merely because it contains the same functional components. The generic sponsor must establish product performance and regulatory acceptability.

Lubricant alternatives

Sodium stearyl fumarate is commercially relevant because it provides lubrication while generally producing less hydrophobicity than prolonged magnesium stearate exposure. Alternatives may reduce cost or improve sourcing resilience, but they can change:

• Tablet ejection force
• Tensile strength
• Disintegration time
• Dissolution rate
• Sensitivity to blending duration

Suppliers that provide narrow particle-size distributions and consistent specific surface area can obtain value through performance qualification rather than ingredient exclusivity.

Film-coating systems

Ready-to-use coating systems can simplify color matching and reduce batch-to-batch variation. Opportunities include:

• Lower titanium dioxide systems
• Titanium-dioxide-free color matching
• Improved opacity at lower coating weight
• Faster coating cycles
• Better resistance to abrasion
• Simplified regulatory documentation

The 40 mg and 80 mg strengths require reliable visual differentiation. Coating suppliers can sell a complete color and process package rather than individual pigments.

Stability and packaging

Osimertinib tablets require stability testing in commercial packaging. Blister systems, high-barrier bottles, desiccants, and moisture-control strategies can create value even when the tablet itself uses standard excipients.

Commercial opportunities include:

• High-barrier unit-dose blister packaging
• Child-resistant packaging
• Calendar packs supporting daily oncology dosing
• Moisture-scavenging closures
• Packaging designed for global climate-zone requirements

Packaging claims may be easier to commercialize than novel excipient claims because they can address handling, adherence, and distribution requirements without materially changing the dosage form.

What formulation changes could create differentiated products?

Tagrisso is administered orally once daily, with or without food, according to the FDA label.[1] A conventional tablet is therefore commercially adequate for most adult patients. Differentiation would need to solve a specific clinical or operational problem.

Pediatric and dysphagia-oriented products

An oral suspension, dispersible tablet, or smaller tablet could address swallowing difficulty or pediatric use. These products would require new development work around:

• Dose flexibility
• Suspension sedimentation
• Taste masking
• Chemical stability in liquid media
• Device compatibility
• Dosing accuracy
• In-use shelf life

A liquid product may create an opportunity for excipient suppliers specializing in suspending agents, sweeteners, flavors, preservatives, and taste-masking systems. It also introduces greater formulation and regulatory complexity than an immediate-release tablet.

Fixed-dose combinations

Osimertinib may be commercially considered for combination products with other oncology agents, but combination formulations face substantial compatibility, dose-ratio, and regulatory challenges. The commercial opportunity is more likely to involve co-packaging or coordinated administration than a single tablet unless clinical and patent conditions support a fixed-dose product.

Abuse-deterrent or modified-release approaches

These approaches have limited apparent commercial rationale for Tagrisso. The drug is a targeted oncology therapy with once-daily dosing, and no established abuse-deterrence requirement drives product demand.

How strong is the Tagrisso patent estate?

The patent estate is commercially meaningful because Tagrisso has major revenue exposure and multiple approved indications. Its strength depends on the specific jurisdiction and claim category.

Patent category	Typical strength	Generic implication
Core compound claims	High if still enforceable	Can block broad generic entry
Salt or solid-form claims	Medium to high	May require alternative API form or litigation
Tablet composition claims	Medium	Design-around may be possible
Method-of-use claims	Variable	Carve-out or restricted labeling may be possible
Dosing-regimen claims	Variable	Relevant to labeled indication strategy
Manufacturing claims	Variable	Can create supply-chain or API risk
Packaging claims	Usually lower	Often easier to design around

The strongest barrier is generally a live, enforceable claim that covers the active ingredient or a necessary pharmaceutical form. Common excipient claims are less likely to prevent a generic launch unless the claim is drafted around a narrow but unavoidable composition range.

What generic entry risks exist for Tagrisso?

Generic entry risk should be modeled in scenarios rather than as a single date.

Scenario 1: At-risk launch

A generic applicant launches before final patent resolution after a Paragraph IV challenge. This can produce rapid market-share capture but exposes the applicant to damages and possible injunction risk.

Scenario 2: Settlement-based launch

A patent settlement permits entry on an agreed date, potentially with limited competition or license terms. The launch date may precede the latest patent expiry but remain later than the generic applicant’s preferred timing.

Scenario 3: Label carve-out

A generic omits one or more patented uses from its labeling. This can permit entry for non-protected indications while limiting promotion and prescription substitution for carved-out uses.

Scenario 4: Delayed multi-source entry

Several applicants enter after key patents expire. Price erosion is usually greater when multiple suppliers launch at the same time, especially when the product has limited formulation differentiation.

For excipient suppliers, the preferred commercial position is qualification across multiple generic programs before launch. A supplier that becomes embedded in a validated commercial process may be harder to replace than one selling a commodity-grade ingredient.

How does Tagrisso compare with other oral oncology products?

Tagrisso is more accessible from a formulation perspective than products requiring complex delivery systems, but its commercial value is higher than the technical difficulty of the tablet suggests.

Product characteristic	Tagrisso	Complex oral oncology product
Dosage form	Immediate-release tablet	May require modified release or lipid delivery
Daily administration	Once daily	Often once or multiple times daily
Excipient complexity	Moderate	Moderate to high
Bioequivalence risk	Meaningful but manageable	Often higher
Taste-masking need	Limited for intact tablets	May be significant
Manufacturing barrier	Conventional solid-dose manufacturing	Specialized process may be needed
Generic opportunity	Strong if patent access is achieved	Depends heavily on formulation know-how

Tagrisso’s opportunity is therefore driven by market size, oncology demand, patent timing, and supply reliability rather than a difficult excipient platform.

What is the revenue exposure associated with Tagrisso?

Tagrisso is one of AstraZeneca’s largest products. AstraZeneca reported Tagrisso product sales of approximately $5.8 billion in 2023.[5] The product is used across EGFR-mutated non-small-cell lung cancer settings, including adjuvant and metastatic disease.

Revenue exposure increases the probability of:

• Multiple generic development programs
• Aggressive Paragraph IV activity
• Early API and excipient capacity reservations
• Formulation supplier competition
• Settlement negotiations
• Regional launch sequencing
• Price pressure after multi-source entry

For investors and suppliers, the key distinction is between total Tagrisso sales and the portion vulnerable to generic substitution. Patent-protected indications, payer controls, launch-at-risk activity, and physician adoption of newer therapies can all affect realized erosion.

Key Takeaways

• Tagrisso is an immediate-release osimertinib mesylate film-coated tablet with a conventional excipient system.
• The core excipients are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate.
• Generic development is technically feasible, but low-dose uniformity, dissolution, stability, and scale-up control remain important.
• The strongest patent barriers are likely to arise from active-ingredient, solid-form, therapeutic-use, and dosing claims rather than ordinary excipient selection.
• Tagrisso is a small molecule, so biosimilar risk does not apply. The relevant pathway is an FDA ANDA.
• Paragraph IV challenges, 30-month stays, settlements, and label carve-outs can materially alter generic launch timing.
• Commercial opportunities exist in co-processed excipients, lubricant systems, film coatings, high-barrier packaging, and pediatric or dysphagia-oriented dosage forms.
• Tagrisso generated approximately $5.8 billion in AstraZeneca sales in 2023, creating substantial generic and supply-chain interest.
• The most defensible excipient opportunity is a validated formulation-and-process package that improves content uniformity, compression, dissolution, or stability.

FAQs

Can a generic Tagrisso use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, quality, labeling, and bioequivalence requirements.

Is mannitol essential to the Tagrisso formulation?

No. Mannitol is a functional diluent and bulking agent, but an applicant may evaluate other diluents if tablet performance and regulatory requirements are satisfied.

Does Tagrisso require a specialized coating polymer?

No. The marketed tablet uses a conventional hypromellose-based film coating. Differentiation may come from coating efficiency, pigment systems, opacity, and process control.

Can a liquid osimertinib product create a new excipient opportunity?

Yes. A liquid or dispersible product would create demand for suspending agents, taste-masking systems, preservatives, flavor systems, and dose-delivery devices. It would also require new stability and in-use testing.

Are Tagrisso generics biosimilars?

No. Osimertinib is a chemically synthesized small molecule. Follow-on products are generics reviewed under the ANDA pathway, not biosimilars reviewed under the biologics framework.

References

1. U.S. Food and Drug Administration. (2024). Tagrisso (osimertinib) prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (2024). New chemical exclusivity determinations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

5. AstraZeneca PLC. (2024). Annual report and Form 20-F for the year ended December 31, 2023. AstraZeneca.